Bevacizumab-Induced Cardiovascular Events: A Consequence of Cholesterol Emboli Syndrome?

Authors:

Abstract
Bevacizumab (Avastin; Genentech, Inc, South San Francisco, CA) is a recombinant monoclonal antibody against vascular endothelial growth factor (VEGF) that is used to treat metastatic cancers of the colon, rectum, kidney, and breast. Its side effects include proteinuria (35% of patients), hypertension (15%–30% of patients), gastrointestinal perforations (5%–7% of patients), and arterial emboli (0.5%–1% of patients) ( 1 – 3 ). Although these toxic effects are more frequent in patients with atherosclerosis, their pathophysiology remains unresolved.

This publication has 7 references indexed in Scilit: